Real -world efficacy of switching to faricimab therapy in patients with longstanding neovascular age -related macular degeneration

被引：0
|
作者：
Long Phan [1 ,2 ]
Chin, Jennifer [1 ]
Hong, Thomas [1 ,2 ]
Chang, Andrew [1 ,2 ]
机构：
[1] CUREOS, Sydney, NSW, Australia
[2] Sydney Retina, Sydney, NSW, Australia
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2024年 / 65卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
234
引用
收藏
页数：4
相关论文
共 50 条
  • [31] BUDGET IMPACT OF FARICIMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) IN IRELAND
    de Greeff, J.
    Goodwin, M.
    VALUE IN HEALTH, 2024, 27 (12)
  • [32] Real -world clinical and anatomical outcomes in patients with neovascular age -related macular degeneration (nAMD) treated with faricimab: The FARETINA-AMD study
    Tabano, David
    Ko, Stella
    Borkar, Durga
    Leng, Theodore
    Ali, Ferhina
    Shaia, Jacqueline K.
    Myers, Rachel
    LaPrise, Andrew
    Singh, Rishi P.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2024, 65 (07)
  • [33] Evaluating Faricimab in Treatment-Naive Neovascular Age Related Macular Degeneration: A Retrospective Analysis of Real-World Data
    Modeste, Danielle
    Stewart, Christopher
    Premanandhan, Hajani
    Awad, Mahmoud Husseiny
    Williams, Gwyn Samuel
    CLINICAL OPHTHALMOLOGY, 2024, 18 : 2821 - 2829
  • [34] COST-EFFECTIVENESS OF FARICIMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN CANADA
    Buhrer, C.
    Paulo, T.
    Diles, D.
    VALUE IN HEALTH, 2022, 25 (12) : S111 - S112
  • [35] Ocular Pharmacodynamics of Intravitreal Faricimab in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema
    Diack, Cheikh
    Avery, Robert L.
    Cheung, Chui Ming Gemmy
    Csaky, Karl G.
    Gibiansky, Leonid
    Jaminion, Felix
    Gibiansky, Ekaterina
    Sickert, Denise
    Stoilov, Ivo
    Cosson, Valerie
    Bogman, Katrijn
    TRANSLATIONAL VISION SCIENCE & TECHNOLOGY, 2024, 13 (11):
  • [36] Intravitreal Faricimab for Previously Treated Neovascular Age-Related Macular Degeneration
    Hang, Abraham
    Ngo, Taylor
    Virk, Jaipreet Singh
    Moussa, Kareem
    Moshiri, Ala
    Emami-Naeini, Parisa
    Park, Susanna S.
    CLINICAL OPHTHALMOLOGY, 2024, 18 : 3781 - 3789
  • [37] Factors Associated with Success of Switching to Faricimab for Neovascular Age-Related Macular Degeneration Refractory to Intravitreal Aflibercept
    Machida, Akira
    Oishi, Akio
    Ikeda, Junichiro
    Kurihara, Junko
    Yoneda, Ai
    Tsuiki, Eiko
    Hirata, Yuki
    Murakami, Ryuya
    Kitaoka, Takashi
    LIFE-BASEL, 2024, 14 (04):
  • [38] One-Year Real-World Outcomes of Intravitreal Faricimab for Previously Treated Neovascular Age-Related Macular Degeneration
    Cancian, Giuseppe
    Paris, Arianna
    Agliati, Lia
    Rizzato, Angelica
    Clerici, Michele
    Volpe, Giulio
    Menghini, Moreno
    Grimaldi, Gabriela
    OPHTHALMOLOGY AND THERAPY, 2024, 13 (11) : 2985 - 2997
  • [39] Two Year Real World Outcomes of Ranibizumab Therapy for Neovascular Age Related Macular Degeneration (nAMD)
    Bhalla, Minak
    Muniraju, Ramu
    OPHTHALMOLOGICA, 2014, 232 : 4 - 4
  • [40] Correction to: Investigation of satisfaction with short‑term outcomes after switching to faricimab to treat neovascular age‑related macular degeneration
    Taiichi Hikichi
    Japanese Journal of Ophthalmology, 2023, 67 (6) : 657 - 657
12345